Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: Normalization by agomelatine

Translational Psychiatry

Volumn 4, Issue 11, 2014, Pages

  Boulle, F ^a,b,c,d   Massart, R ^e   Stragier, E ^a,d   Paizanis E ^a,d   Zaidan, L ^a,d   Marday, S ^a,d   Gabriel, C ^f   Mocaer, E ^f   Mongeau, R ^a,d   Lanfumey, L ^a,d  

^a INSERM   (France)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c European Graduate School for Neuroscience   (Netherlands)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e MCGILL UNIVERSITY   (Canada)

^f IRIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; AGOMELATINE; BETA TUBULIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA METHYLTRANSFERASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HISTONE DEACETYLASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROGENIC DIFFERENTIATION FACTOR; PROTEIN BCL 2; PROTEIN KINASE B; SOMATOMEDIN C; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; MELATONIN RECEPTOR; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; ENVIRONMENTAL STRESS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPUS; HYPERACTIVITY; IMMOBILITY; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AFFECTIVE SYMPTOMS; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; COMPLICATION; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; GENETIC EPIGENESIS; MENTAL STRESS; METABOLISM; PHYSIOLOGY; PSYCHOMOTOR AGITATION; SIGNAL TRANSDUCTION;

ACETAMIDES; AFFECTIVE SYMPTOMS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; NEURONAL PLASTICITY; PSYCHOMOTOR AGITATION; RECEPTORS, MELATONIN; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 84927724839     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.125     Document Type: Article

References (54)

1. Gunnar M, Quevedo K. The neurobiology of stress and development. Annu Rev Psychol 2007; 58: 145-173.
2. McEwen BS, Gould EA, Sakai RR. The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. Br J Psychiatry Suppl 1992; 15: 18-23.
3. Sala M, Perez J, Soloff P, Ucelli di Nemi S, Caverzasi E, Soares JC et al. Stress and hippocampal abnormalities in psychiatric disorders. Eur Neuropsychopharmacol 2004; 14: 393-405.
4. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007; 87: 873-904.
5. Apfel BA, Ross J, Hlavin J, Meyerhoff DJ, Metzler TJ, Marmar CR et al. Hippocampal volume differences in Gulf War veterans with current versus lifetime posttraumatic stress disorder symptoms. Biol Psychiatry 2011; 69: 541-548.
6. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004; 56: 640-650.
7. Malkoff-Schwartz S, Frank E, Anderson B, Sherrill JT, Siegel L, Patterson D et al. Stressful life events and social rhythm disruption in the onset of manic and depressive bipolar episodes: a preliminary investigation. Arch Gen Psychiatry 1998; 55: 702-707.
8. Proudfoot J, Doran J, Manicavasagar V, Parker G. The precipitants of manic/hypomanic episodes in the context of bipolar disorder: a review. J Affect Disord 2011; 133: 381-387.
9. Maze I, Noh KM, Allis CD. Histone regulation in the CNS: basic principles of epigenetic plasticity. Neuropsychopharmacology 2013; 38: 3-22.
10. Boulle F, van den Hove DL, Jakob SB, Rutten BP, Hamon M, van Os J et al. Epigenetic regulation of the BDNF gene: implications for psychiatric disorders. Mol Psychiatry 2012; 17: 584-596.
11. Vialou V, Feng J, Robison AJ, Nestler EJ. Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol 2013; 53: 59-87.
12. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010; 9: 628-642.
13. Musshoff U, Riewenherm D, Berger E, Fauteck JD, Speckmann EJ. Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 2002; 12: 165-173.
14. Berumen LC, Rodriguez A, Miledi R, Garcia-Alcocer G. Serotonin receptors in hippocampus. ScientificWorldJournal 2012; 2012: 823493.
15. Bertaina-Anglade V, la Rochelle CD, Boyer PA, Mocaer E. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 2006; 17: 703-713.
16. Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009; 34: 2390-2403.
17. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008; 165: 820-829.
18. Lanfumey L, Mongeau R, Hamon M. Biological rhythms and melatonin in mood disorders and their treatments. Pharmacol Ther 2013; 138: 176-184.
19. Froger N, Palazzo E, Boni C, Hanoun N, Saurini F, Joubert C et al. Neurochemical and behavioral alterations in glucocorticoid receptor-impaired transgenic mice after chronic mild stress. J Neurosci 2004; 24: 2787-2796.
20. Pardon MC, Perez-Diaz F, Joubert C, Cohen-Salmon C. Influence of a chronic ultramild stress procedure on decision-making in mice. J Psychiatry Neurosci 2000; 25: 167-177.
21. Willner P. Chronic mild stress (CMS) revisited: consistency and behaviouralneurobiological concordance in the effects of CMS. Neuropsychobiology 2005; 52: 90-110.
22. Paizanis E, Renoir T, Lelievre V, Saurini F, Melfort M, Gabriel C et al. Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol 2010; 13: 759-774.
23. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates, 3rd edn. Elsevier Academic Press: San Diego, CA, USA, 2007.
24. Calabrese F, Molteni R, Racagni G, Riva M.A. Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 2009; 34(Suppl 1): S208-S216.
25. Touma C. Stress and affective disorders: animal models elucidating the molecular basis of neuroendocrine-behavior interactions. Pharmacopsychiatry 2011; 44 (Suppl 1): S15-S26.
26. Yalcin I, Belzung C, Surget A. Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav Brain Res 2008; 193: 140-143.
27. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625.
28. Narboux-Neme N, Sagne C, Doly S, Diaz SL, Martin CB, Angenard G et al. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences. Neuropsychopharmacology 2011; 36: 2538-2550.
29. Negroni J, Venault P, Pardon MC, Perez-Diaz F, Chapouthier G, Cohen-Salmon C. Chronic ultra-mild stress improves locomotor performance of B6D2F1 mice in a motor risk situation. Behav Brain Res 2004; 155: 265-273.
30. Gronli J, Murison R, Fiske E, Bjorvatn B, Sorensen E, Portas CM et al. Effects of chronic mild stress on sexual behavior, locomotor activity and consumption of sucrose and saccharine solutions. Physiol Behav 2005; 84: 571-577.
31. van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc Natl Acad Sci USA 1999; 96: 13427-13431.
32. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004; 5: 173-183.
33. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459: 55-60.
34. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519-525.
35. Van den Hove DL, Kenis G, Brass A, Opstelten R, Rutten BP, Bruschettini M et al. Vulnerability versus resilience to prenatal stress in male and female rats; implications from gene expression profiles in the hippocampus and frontal cortex. Eur Neuropsychopharmacol 2013; 23: 1226-1246.
36. Suri D, Bhattacharya A, Vaidya VA. Early stress evokes temporally distinct consequences on the hippocampal transcriptome, anxiety and cognitive behaviour. Int J Neuropsychopharmacol 2014; 17: 289-301.
37. Covington HE 3rd, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009; 29: 11451-11460.
38. Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K et al. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 2010; 44: 263-270.
39. Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrie P. Blockade of CRF (1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2004; 9: 278-286.
40. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008; 13: 717-728.
41. Sunanda, Rao MS, Raju TR. Effect of chronic restraint stress on dendritic spines and excrescences of hippocampal CA3 pyramidal neurons-a quantitative study. Brain Res 1995; 694: 312-317.
42. Fitzsimons CP, van Hooijdonk LW, Schouten M, Zalachoras I, Brinks V, Zheng T et al. Knockdown of the glucocorticoid receptor alters functional integration of newborn neurons in the adult hippocampus and impairs fear-motivated behavior. Mol Psychiatry 2013; 18: 993-1005.
43. Krugers HJ, Goltstein PM, van der Linden S, Joels M. Blockade of glucocorticoid receptors rapidly restores hippocampal CA1 synaptic plasticity after exposure to chronic stress. Eur J Neurosci 2006; 23: 3051-3055.
44. Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006; 59: 1087-1096.
45. Gumuslu E, Mutlu O, Sunnetci D, Ulak G, Celikyurt IK, Cine N et al. The antidepressant agomelatine improves memory deterioration and upregulates CREB and BDNF gene expression levels in unpredictable chronic mild stress (UCMS)-exposed mice. Drug Target Insights 2014; 8: 11-21.
46. Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G et al. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009; 34: 1363-1380.
47. Mairesse J, Silletti V, Laloux C, Zuena AR, Giovine A, Consolazione M et al. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats. Int J Neuropsychopharmacol 2013; 16: 323-338.
48. Freitas AE, Machado DG, Budni J, Neis VB, Balen GO, Lopes MW et al. Fluoxetine modulates hippocampal cell signaling pathways implicated in neuroplasticity in olfactory bulbectomized mice. Behav Brain Res 2013; 237: 176-184.
49. Boer U, Cierny I, Krause D, Heinrich A, Lin H, Mayr G et al. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacology 2008; 33: 2407-2415.
50. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-964.
51. Norman TR, Cranston I, Irons JA, Gabriel C, Dekeyne A, Millan MJ et al. Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006. Eur J Pharmacol 2011; 674: 27-32.
52. Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 2013; 38: 275-284.
53. Kirshenbaum GS, Clapcote SJ, Duffy S, Burgess CR, Petersen J, Jarowek KJ et al. Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+, K +-ATPase alpha3 sodium pump. Proc Natl Acad Sci USA 2011; 108: 18144-18149.
54. Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006; 26: 9022-9029.